Kymera Total Assets from 2010 to 2025
| KYMR Stock | USD 40.61 0.32 0.79% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 662.1 M | Current Value 446 M | Quarterly Volatility 260.8 M |
Check Kymera Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kymera Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 22.4 M, Interest Income of 22.7 M or Depreciation And Amortization of 2.3 M, as well as many indicators such as Price To Sales Ratio of 20.66, Dividend Yield of 0.0 or PTB Ratio of 3.56. Kymera financial statements analysis is a perfect complement when working with Kymera Therapeutics Valuation or Volatility modules.
Kymera | Total Assets |
Latest Kymera Therapeutics' Total Assets Growth Pattern
Below is the plot of the Total Assets of Kymera Therapeutics over the last few years. Total assets refers to the total amount of Kymera Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Kymera Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Kymera Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kymera Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 575.76 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Kymera Total Assets Regression Statistics
| Arithmetic Mean | 243,431,851 | |
| Geometric Mean | 121,612,799 | |
| Coefficient Of Variation | 107.13 | |
| Mean Deviation | 239,942,189 | |
| Median | 44,231,000 | |
| Standard Deviation | 260,788,935 | |
| Sample Variance | 68010.9T | |
| Range | 617.9M | |
| R-Value | 0.84 | |
| Mean Square Error | 21413.1T | |
| R-Squared | 0.71 | |
| Significance | 0.000046 | |
| Slope | 46,030,010 | |
| Total Sum of Squares | 1020163T |
Kymera Total Assets History
Other Fundumenentals of Kymera Therapeutics
Kymera Therapeutics Total Assets component correlations
Click cells to compare fundamentals
About Kymera Therapeutics Financial Statements
Kymera Therapeutics shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Kymera Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Kymera Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Kymera Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 662.1 M | 446 M |
Pair Trading with Kymera Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Kymera Stock
Moving against Kymera Stock
| 0.73 | DRTS | Alpha Tau Medical | PairCorr |
| 0.73 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.58 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.52 | VCEL | Vericel Corp Ord | PairCorr |
| 0.52 | SABSW | SAB Biotherapeutics | PairCorr |
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.